Back to top
more

Outset Medical (OM)

(Delayed Data from NSDQ)

$2.40 USD

2.40
402,980

+0.02 (0.84%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $2.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis

by Zacks Equity Research

Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.

Inspire (INSP) Surges 9.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Inspire (INSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal fourth-quarter sales.

Analysts Estimate Olink Holding AB (publ) Sponsored ADR (OLK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Olink Holding AB (publ) Sponsored ADR (OLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

After Plunging -62.36% in 4 Weeks, Here's Why the Trend Might Reverse for Outset Medical, Inc. (OM)

by Zacks Equity Research

Outset Medical, Inc. (OM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down -68.16% in 4 Weeks, Here's Why You Should You Buy the Dip in Outset Medical, Inc. (OM)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Outset Medical, Inc. (OM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Outset Medical, Inc. (OM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of 5.48% and 2.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Outset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -4.35% and 6.25%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Outset Medical, Inc. (OM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of 6.58% and 1.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Computer Programs and Systems (CPSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Computer Programs and Systems (CPSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Outset Medical, Inc. (OM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Outset Medical, Inc. (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Outset Medical, Inc. (OM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of 1.41% and 9.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Change Healthcare (CHNG) Soars 6.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Change Healthcare (CHNG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Outset Medical, Inc. (OM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -22.22% and 2.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Does Outset Medical, Inc. (OM) Have the Potential to Rally 94% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Outset Medical, Inc. (OM) points to a 93.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Industry Outlook Highlights Omnicell, Axonics and Outset Medical

by Zacks Equity Research

Omnicell, Axonics and Outset Medical have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info System Stocks Braving Industry Headwinds

by Urmimala Biswas

Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.

Outset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -1.52% and 0.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Invitae (NVTA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Invitae (NVTA) delivered earnings and revenue surprises of -1.30% and 2.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Outset Medical, Inc. (OM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Outset Medical, Inc. (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Outset Medical, Inc. (OM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -14.93% and 6.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Outset Medical, Inc. (OM) Q4 Earnings Expected to Decline

by Zacks Equity Research

Outset Medical, Inc. (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Predict a 27% Upside in Outset Medical, Inc. (OM): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 27.4% upside potential for Outset Medical, Inc. (OM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.